Stock Analysis on Net

Thermo Fisher Scientific Inc. (NYSE:TMO)

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Thermo Fisher Scientific Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

Microsoft Excel
Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022 Dec 31, 2021 Oct 2, 2021 Jul 3, 2021 Apr 3, 2021 Dec 31, 2020 Sep 26, 2020 Jun 27, 2020 Mar 28, 2020
Short-term obligations and current maturities of long-term obligations 2,214 4,116 5,121 4,451 3,609 4,795 4,814 6,122 5,579 1,010 1,010 1,866 2,537 19 4 4 2,628 2 675 738
Accounts payable 3,079 2,606 2,547 2,555 2,872 2,508 2,423 2,798 3,381 2,471 2,586 2,667 2,867 2,301 2,098 2,146 2,175 1,703 1,385 1,599
Accrued payroll and employee benefits 1,988 1,823 1,495 1,314 1,596 1,460 1,310 1,307 2,095 1,864 1,722 1,634 2,427 1,816 1,492 1,314 1,916 1,538 1,184 755
Contract liabilities 2,852 2,663 2,591 2,632 2,689 2,547 2,590 2,662 2,601 2,567 2,722 2,871 2,655 1,442 1,470 1,396 1,271 1,047 975 938
Other accrued expenses 3,199 3,393 3,018 2,985 3,246 2,848 2,975 2,995 3,354 3,206 2,957 3,032 2,950 2,175 1,861 2,135 2,314 1,938 1,794 1,470
Current liabilities 13,332 14,601 14,772 13,937 14,012 14,158 14,112 15,884 17,010 11,118 10,997 12,070 13,436 7,753 6,925 6,995 10,304 6,228 6,013 5,500
Deferred income taxes 1,268 1,123 1,516 1,811 1,922 2,620 2,842 2,976 2,849 3,140 3,327 3,493 3,837 1,465 1,632 1,885 1,794 1,528 1,750 2,137
Other long-term liabilities 3,989 4,344 4,391 4,567 4,642 4,326 4,042 4,230 4,238 4,401 4,534 4,664 4,540 3,984 3,514 3,352 3,340 3,390 3,317 3,261
Long-term obligations, excluding current maturities 29,061 31,197 30,284 31,157 31,308 30,489 29,194 29,135 28,909 28,150 29,250 31,389 32,333 21,688 18,773 18,641 19,107 21,091 20,638 19,231
Long-term liabilities 34,318 36,664 36,191 37,535 37,872 37,435 36,078 36,341 35,996 35,691 37,111 39,546 40,710 27,137 23,919 23,878 24,241 26,009 25,705 24,629
Total liabilities 47,650 51,265 50,963 51,472 51,884 51,593 50,190 52,225 53,006 46,809 48,108 51,616 54,146 34,890 30,844 30,873 34,545 32,237 31,718 30,129
Redeemable noncontrolling interest 120 127 114 119 118 118 113 123 116 119 117 113 122
Preferred stock, $100 par value; none issued
Common stock, $1 par value 444 444 443 443 442 442 441 441 441 440 440 440 439 439 438 438 437 437 436 435
Capital in excess of par value 17,962 17,831 17,649 17,482 17,286 17,165 17,030 16,889 16,743 16,596 16,467 16,292 16,174 15,960 15,826 15,684 15,579 15,467 15,334 15,186
Retained earnings 53,101 51,421 49,940 48,541 47,364 45,869 44,289 43,064 41,910 40,452 39,074 37,528 35,431 33,876 32,076 30,350 28,116 25,705 23,860 22,791
Treasury stock at cost (19,226) (18,227) (18,187) (18,186) (15,133) (15,121) (15,084) (15,083) (12,017) (11,011) (10,964) (10,961) (8,922) (8,911) (8,856) (8,852) (6,818) (6,815) (6,766) (6,765)
Accumulated other comprehensive loss (2,697) (2,477) (2,413) (2,764) (3,224) (3,027) (2,924) (3,054) (3,099) (2,928) (2,724) (2,343) (2,329) (2,654) (2,630) (2,562) (2,807) (2,970) (2,989) (3,088)
Total Thermo Fisher Scientific Inc. shareholders’ equity 49,584 48,992 47,432 45,516 46,735 45,328 43,752 42,257 43,978 43,549 42,293 40,956 40,793 38,710 36,854 35,058 34,507 31,824 29,875 28,559
Noncontrolling interests (33) (20) (13) (12) (11) 18 50 53 54 59 61 62 62
Total equity 49,551 48,972 47,419 45,504 46,724 45,346 43,802 42,310 44,032 43,608 42,354 41,018 40,855 38,710 36,854 35,058 34,507 31,824 29,875 28,559
Total liabilities, redeemable noncontrolling interest and equity 97,321 100,364 98,496 97,095 98,726 97,057 94,105 94,658 97,154 90,536 90,579 92,747 95,123 73,600 67,698 65,931 69,052 64,061 61,593 58,688

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-26), 10-Q (reporting date: 2020-06-27), 10-Q (reporting date: 2020-03-28).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Thermo Fisher Scientific Inc. current liabilities decreased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Thermo Fisher Scientific Inc. long-term liabilities increased from Q2 2024 to Q3 2024 but then decreased significantly from Q3 2024 to Q4 2024.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Thermo Fisher Scientific Inc. total liabilities increased from Q2 2024 to Q3 2024 but then decreased significantly from Q3 2024 to Q4 2024.
Total Thermo Fisher Scientific Inc. shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Thermo Fisher Scientific Inc. total Thermo Fisher Scientific Inc. shareholders’ equity increased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.